Roy Anderson - GLAXOSMITHKLINE PLC Non-Executive Independent Director


GBp 1,342  35.80  2.74%   

Prof. Sir Roy Malcolm Anderson is NonExecutive Independent Director of GlaxoSmithKline Plc., since 1 October 2007. Professor Sir Roy is a worldrenowned medical scientist with advanced knowledge of infectious disease epidemiology, and is currently Professor of Infectious Disease in the Faculty of Medicine, Imperial College, London. He is a Fellow of the Royal Society, the Academy of Medical Sciences and the Royal Statistical Society. He is an Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the National Academy of Medicine at the US National Academy of Sciences and the French Academy of Sciences. Professor Sir Roy brings scientific expertise to the Boards deliberations. Professor Sir Roy is a member of the Holdingham International Advisory Board and a member of the Science Advisory Board of the Natural History Museum, London. He is also a member of the Vaccine International Advisory Board of AJ Pharma Holding Sdn. Bhd in Malaysia, the International Alzheimers Consortium at Harvard University, Boston, Chairman of the Scientific Advisory Board of the Netherlands Centre for One Health and Chairman of Oriole Global Health Ltd.
Age: 69  Director Since 2007      
(44) 20 8047 7807

GLAXOSMITHKLINE PLC Management Efficiency

GLAXOSMITHKLINE PLC ORD has return on total asset (ROA) of 6.58 % which means that it generated profit of $6.58 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 24.71 %, meaning that it generated $24.71 on every $100 dollars invested by stockholders. GLAXOSMITHKLINE PLC management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 22.11 B in total debt with debt to equity ratio (D/E) of 0.98, which is about average as compared to similar companies. GLAXOSMITHKLINE PLC ORD has a current ratio of 1.4, which is within standard range for the sector. Debt can assist GLAXOSMITHKLINE PLC until it has trouble settling it off, either with new capital or with free cash flow. So, GLAXOSMITHKLINE PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GLAXOSMITHKLINE PLC ORD sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GLAXOSMITHKLINE to invest in growth at high rates of return. When we think about GLAXOSMITHKLINE PLC's use of debt, we should always consider it together with cash and equity.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GLAXOSMITHKLINE PLC operates under Pharmaceuticals And Biosciences classification in UK and is traded on London Stock Exchange. It employs 90096 people. GLAXOSMITHKLINE PLC ORD (GSK) is traded on London Stock Exchange in UK and employs 90,096 people.


Elected by the shareholders, the GLAXOSMITHKLINE PLC's board of directors comprises two types of representatives: GLAXOSMITHKLINE PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GLAXOSMITHKLINE. The board's role is to monitor GLAXOSMITHKLINE PLC's management team and ensure that shareholders' interests are well served. GLAXOSMITHKLINE PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GLAXOSMITHKLINE PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vindi Banga, Senior Independent Non-Executive Director
Lynn Elsenhans, Independent Non-Executive Director
Luke Miels, President - Global Pharmaceuticals
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director
Daniel Podolsky, Non-Executive Independent Director
Emma Walmsley, Chief Executive Officer, Executive Director
Luc Debruyne, President - Global Vaccines
Andrew Witty, CEO, Executive Director
Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare
Charles Bancroft, Non-Executive Director
Roy Anderson, Non-Executive Independent Director
Philip Hampton, Independent Non-Executive Director
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox, Non-Executive Independent Director
Bill Louv, Senior Vice President - Core Business Services
Diana Conrad, Senior Vice President - Human Resources
Roger Connor, President - Global Manufacturing & Supply
Abbas Hussain, President Global Pharmaceuticals
Phil Thomson, Senior Vice President - Global Communications
Judy Lewent, Non-Executive Independent Director
Hans Wijers, Independent Non-Executive Director
Stephanie Burns, Non-Executive Independent Director
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Urs Rohner, Non-Executive Independent Director
Marvinder Banga, Senior Non-Executive Independent Director
Deryck Maughan, Senior Independent Non-Executive Director
Jesse Goodman, Non-Executive Independent Director
Laurie Glimcher, Non-Executive Independent Director
Nick Hirons, Senior Vice President - Global Ethics and Compliance
Sally Jackson, Senior Vice President - Global Communications and CEO Office
James Ford, Senior Vice President General Counsel
Victoria Whyte, Company Secretary
Daniel Troy, Sr. VP and General Counsel
Shah Hussain, President - Europe, Japan & EMAP
Manvinder Banga, Non-Executive Director
David Redfern, Chief Strategy Officer
Patrick Vallance, President - Pharmaceuticals R&D
Stacey Cartwright, Non-Executive Independent Director
Regis Simard, President - Pharmaceutical Supply Chain
Jonathan Symonds, Independent Non-Executive Chairman of the Board
Iain Mackay, Chief Financial Officer, Executive Director
Karenann Terrell, Chief Digital & Technology Officer
Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare
Claire Thomas, Senior Vice President - Human Resources

GLAXOSMITHKLINE Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GLAXOSMITHKLINE PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GLAXOSMITHKLINE PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GLAXOSMITHKLINE PLC's short interest history, or implied volatility extrapolated from GLAXOSMITHKLINE PLC options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as GLAXOSMITHKLINE PLC ORD using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for analysis

When running GLAXOSMITHKLINE PLC ORD price analysis, check to measure GLAXOSMITHKLINE PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GLAXOSMITHKLINE PLC is operating at the current time. Most of GLAXOSMITHKLINE PLC's value examination focuses on studying past and present price action to predict the probability of GLAXOSMITHKLINE PLC's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move GLAXOSMITHKLINE PLC's price. Additionally, you may evaluate how the addition of GLAXOSMITHKLINE PLC to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Please note, there is a significant difference between GLAXOSMITHKLINE PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine GLAXOSMITHKLINE PLC value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GLAXOSMITHKLINE PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.